Artiva Biotherapeutics, Inc. (ARTV) NASDAQ
5.45
+0.44(+8.78%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.45
+0.44(+8.78%)
Currency In USD
| Previous Close | 5.01 |
| Open | 5.07 |
| Day High | 5.64 |
| Day Low | 5.07 |
| 52-Week High | 7.75 |
| 52-Week Low | 1.47 |
| Volume | 174,296 |
| Average Volume | 184,438 |
| Market Cap | 134.71M |
| PE | -1.59 |
| EPS | -3.43 |
| Moving Average 50 Days | 4.95 |
| Moving Average 200 Days | 3.58 |
| Change | 0.44 |
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 25, 2026 1:00 PM GMT
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune dise
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoim
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
GlobeNewswire Inc.
Feb 19, 2026 1:00 PM GMT
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoim